Top

Published in:

01-12-2019 | Multiple Sclerosis | Letter to the Editors

Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer

Authors: Marzia Anita Lucia Romeo, Marina Chiara Garassino, Lucia Moiola, Giulia Galli, Giancarlo Comi, Vittorio Martinelli, Massimo Filippi

Published in: Journal of Neurology | Issue 12/2019

Excerpt

Dear Sirs, …

Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454CrossRef

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med 375:1823–1833CrossRef

Baxi S, Yang A, Gennarelli RL et al (2018) Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 360:k793CrossRef

Fellner A, Makranz C, Lotem M et al (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol 137:601–609CrossRef

Garcia CR, Jayswal R, Adams V, Antony LB, Villano JL (2019) Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol. https://doi.org/10.1007/s12094-019-02060-8 CrossRefPubMedPubMedCentral

Gómez Vicente L, Rubio Viqueira B, De Las Jimenez, Peñas M et al (2016) Relapse in a paucisymptomatic form of multiple sclerosis in a patient treated with nivolumab. Neuro-oncology 18:iv25CrossRef

Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173CrossRef

Trabattoni D, Saresella M, Pacei M et al (2009) Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol 183:4984–4993CrossRef

Takizawa S, Kaneyama T, Tsugane S et al (2014) Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler’s murine encephalomyelitis virus-induced demyelinating disease. J Neuroimmunol 274:78–85CrossRef

10.

Cortese I, Muranski P, Enose-Akahata Y et al (2019) Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med 380:1597–1605CrossRef

Title: Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer
Authors: Marzia Anita Lucia Romeo
Marina Chiara Garassino
Lucia Moiola
Giulia Galli
Giancarlo Comi
Vittorio Martinelli
Massimo Filippi
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Sclerosis
NSCLC
Demyelinating Disease
NSCLC
Natalizumab
Checkpoint Inhibitors
Published in: Journal of Neurology / Issue 12/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09562-z

At a glance: The STEP trials

Springer Medicine

Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2019

High-dose steroid therapy for CNS inflammatory diseases increases INR in patients taking oral vitamin K antagonist

Deterioration of specific aspects of gait during the instrumented 6-min walk test among people with multiple sclerosis

Early MRI predictors of prognosis in multiple sclerosis

Trajectories of brain remodeling in temporal lobe epilepsy

Unexpected emergence from the vegetative state: delayed discovery rather than late recovery of consciousness

Spinal cord lesions are frequently asymptomatic in relapsing–remitting multiple sclerosis: a retrospective MRI survey